Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

ADJUSTMENT OF THE STRATEGIC COMMITTEE TO THE STRATEGIC AND ESG COMMITTEE; AMENDMENTS TO AND FORMULATION OF CERTAIN INTERNAL MANAGEMENT POLICIES

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") pursuant to Rule 13.51 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Reference is also made to the overseas regulatory announcement of the Company dated 13 March 2026.

(1) ADJUSTMENT OF THE STRATEGIC COMMITTEE TO THE STRATEGIC AND ESG COMMITTEE

The board (the "**Board**") of directors (the "**Directors**") of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") is pleased to announce that, in order to further enhance the Company's level of environmental, social and governance ("**ESG**") management, and to strengthen the Company's sustainable development capabilities, pursuant to the provisions of relevant laws and the articles of association of the Company (the "**Articles of Association**") and taking into account of the actual situation of the Company, the Board has resolved to adjust the original strategic committee (the "**Strategic Committee**") under the Board to the strategic and ESG committee (the "**Strategic and ESG Committee**") with effect from 13 March 2026, and to adjust the original Terms of Reference of the Strategic Committee to the Terms of Reference of the Strategic and ESG Committee, with the addition of duties such as ESG management on the basis of its original powers and functions.

The Strategic and ESG Committee is primarily responsible for studying the Company's long-term development strategy, major investment decisions, sustainable development and ESG, as well as making recommendations to the Board. The adjustment only involves adjustments to the committee's name and responsibilities, while its composition, term of office and other requirements will remain unchanged.

The adjusted Terms of Reference of the Strategic and ESG Committee are available on the website of the Company (www.junshipharma.com), the website of The Stock Exchange of Hong Kong Limited (www.hkex.com.hk) and the website of the Shanghai Stock Exchange (www.sse.com.cn).

(2) FORMULATION OF THE REMUNERATION POLICIES OF DIRECTORS AND SENIOR MANAGEMENT

In order to further optimize the remuneration management of Directors and senior management of the Company, establish a scientific and effective incentive and restraint mechanism, foster the enthusiasm and innovation of Directors and senior management, and enhance corporate operational efficiency and management, pursuant to the provisions of relevant laws and the Articles of Association and taking into account of the actual situation, the Company has formulated the Remuneration Policies of Directors and Senior Management. The formulation of these policies has been reviewed and approved by the Board, and shall be subject to the approval of the shareholders of the Company by way of ordinary resolution at a general meeting to be convened by the Company. A circular containing, among other things, details of these policies will be issued to the shareholders of the Company as soon as practicable.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 13 March 2026

As at the date of this announcement, the Board of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purposes only*